Bio-Path Holdings is an oncology-focused biotechnology company based in Houston, TX, that is revolutionizing cancer treatment through its innovative DNAbilize platform technology. Their lead candidate, prexigebersen, is being evaluated in a Phase 2 trial for the treatment of acute myeloid leukemia, while their second product, BP1002, is undergoing Phase 1 trials for lymphoma and AML. With a mission to provide non-toxic therapies for fragile cancer patients who are ineligible for high-dose chemotherapy, Bio-Path aims to deliver targeted cancer treatments that offer effective therapy without harsh side effects. Their pipeline consists of antisense RNAi nanoparticle drugs, offering hope for patients with some of the most lethal blood cancers and solid tumors.Generated from the website